New Podcast CE/CME Alert: "Medications for Opioid Use Disorder" is now available! Listen for FREE now. Subscribers can earn CE credits just for listening and passing a short quiz.

Expert-based medication knowledge at your fingertips! More CE, more resources, more value. Choose your Prescriber Insights membership and get the tools you need for success today. Subscribe Now

Know How COVID-19 Oral Antivirals Compare

February 2022

You'll start to see the new COVID-19 oral antivirals, nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.

Either is an option for outpatients with COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.

They're started within 5 days of symptoms...and patients don't currently have to pay for these meds.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote